ArticleAntibiotics (Basel, Switzerland)2023
Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis.
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06590428 (Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Adverse Drug Reaction to Linezolid in Drug-Resistant Tuberculosis: A Systematic Review.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Linezolid-Induced Optic Neuritis in Tuberculosis: A Systematic Review of Case Reports, Case Series, and Cohort Studies.Tuberculosis and respiratory diseases · 2026Article
- Adverse effects of linezolid in the treatment of drug-resistant tuberculosis: a scoping review.Breathe (Sheffield, England) · 2026Review
- Incidence and sex-related risk factors of linezolid-associated adverse drug reactions identified through electronic health records.Translational and clinical pharmacology · 2026Article
- Therapeutic Drug Monitoring for Improving Tuberculosis Treatment Outcomes: A Scoping Review of Clinical Studies.Clinical pharmacokinetics · 2026Article
- Linezolid Related Adverse Effects in Different Populations: A Review.Current drug safety · 2026Review
- Article
- Therapeutic Drug Monitoring of Linezolid in Drug-Resistant Tuberculosis Patients: Clinical Factors and Hematological Toxicities.Infection and drug resistance · 2024Article
- Pharmacokinetics and Safety of Group A and B Anti-Tuberculosis Drugs Used in Treatment of Rifampicin-Resistant Tuberculosis during Pregnancy and Post-Partum: A Narrative Review.Pathogens (Basel, Switzerland) · 2023Review
- Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects.The Journal of antimicrobial chemotherapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
We evaluated the relationship between the pharmacokinetic parameters of linezolid (LZD) and development of adverse drug reactions (ADRs) in patients with pulmonary drug-resistant tuberculosis. A prospective cohort of adults with pulmonary multidrug-resistant tuberculosis with additional resistance to fluoroquinolone (MDR-TB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.